tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
REGN is currently covered by 19 analysts with an average price target of $824.44. This is a potential upside of $126.83 (24.07%) from yesterday's end of day stock price of $664.52.
Regeneron Pharmaceuticals's activity chart (see below) currently has 804 price targets and 589 ratings on display. The stock rating distribution of REGN is 28.13% HOLD, 70.31% BUY and 1.56% SELL.
Analysts average stock forecasts to be materialized ratio is 82.66% with an average time for these price targets to be met of 228.27 days.
Highest price target for REGN is $995, Lowest price target is $627, average price target is $824.44.
Most recent stock forecast was given by BIREN AMIN from PIPER SANDLER on 09-Jul-2026. First documented stock forecast 30-Sep-2013.
Regeneron Pharmaceuticals specializes in products that enable minimally invasive care.
The da Vinci Surgical System is a robotic surgical system that includes:
The surgeon uses the console to control the instruments, which are inserted into the patient’s body through small incisions. The system allows for greater precision and control during surgery, resulting in reduced trauma to the patient and faster recovery times.
The Ion endoluminal system enables minimally invasive biopsies in the lung, which can help diagnose lung cancer and other conditions.
Intuitive Surgical also provides a suite of stapling, energy, and core instrumentation for its surgical systems, as well as progressive learning pathways to support the use of its technology. The company offers a complement of services to its customers, including support, installation, repair, and maintenance, to ensure that its products operate efficiently and effectively.
Moreover, Intuitive Surgical has integrated digital capabilities providing connected offerings that streamline performance for hospitals with program-enhancing insights.
The company was founded in 1995 and is headquartered in Sunnyvale, California.
Currently out of the existing stock ratings of REGN, 18 are a HOLD (28.13%), 45 are a BUY (70.31%), 1 are a SELL (1.56%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 24-Feb-2020
$854
$189.48 (28.51%)
$875
3 days ago
(09-Jul-2026)
6/9 (66.67%)
$186.05 (27.85%)
415
Hold Since 11-Dec-2025
$730
$65.48 (9.85%)
$796
4 days ago
(08-Jul-2026)
49/57 (85.96%)
$67.12 (10.13%)
202
Hold Since 02-Jun-2025
$696
$31.48 (4.74%)
$762
5 days ago
(07-Jul-2026)
23/41 (56.1%)
$19.77 (2.92%)
78
Buy Since 23-Nov-2025
$769
$104.48 (15.72%)
$796
5 days ago
(07-Jul-2026)
1/6 (16.67%)
$92.77 (13.72%)
44
Buy Since 08-Mar-2017
$750
$85.48 (12.86%)
$800
6 days ago
(06-Jul-2026)
26/31 (83.87%)
$100.19 (15.42%)
202
What is REGN (Regeneron Pharmaceuticals) average time for price targets to be met?
Which analyst has the current highest performing score on REGN (Regeneron Pharmaceuticals) with a proven track record?
Which analyst has the most public recommendations on REGN (Regeneron Pharmaceuticals)?
Which analyst is the currently most bullish on REGN (Regeneron Pharmaceuticals)?
Which analyst is the currently most reserved on REGN (Regeneron Pharmaceuticals)?
